Skip to content

News & Events

Academic Urology Research Investigators Consortium (AURIC)

Watch AURIC Director Dr. Thomas Flaig Discuss Recent Developments in Bladder Cancer Treatment
Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses recent developments in bladder cancer treatment, including immune checkpoint inhibitors. 
Watch AURIC Director Dr. Thomas Flaig Discuss the Role of Antibody-Drug Conjugates in Advanced Urothelial Cancer
Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses how antibody-drug conjugates are used in the treatment of advanced urothelial cancer.
Interview with Dr. Matthew Milowsky of the Academic Urology Research Investigators Consortium (AURIC)
Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab.
AURIC Investigator’s Meeting – Successful First Meeting of Newly Formed Group
The Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.
Thomas Flaig, MD
Management of toxicities with novel systemic therapies in UC
AURIC Director Thomas Flaig, MD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease.